Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 23;11(10):2933.
doi: 10.3390/jcm11102933.

Lymphocyte Medium-Chain Acyl-CoA Dehydrogenase Activity and Its Potential as a Diagnostic Confirmation Tool in Newborn Screening Cases

Patricia Alcaide  1 , Isaac Ferrer-López  1 , Leticia Gutierrez  1 , Fatima Leal  1 , Elena Martín-Hernández  2 , Pilar Quijada-Fraile  2 , Marcello Bellusci  2 , Ana Moráis  3 , Consuelo Pedrón-Giner  4 , Dolores Rausell  5 , Patricia Correcher  5 , María Unceta  6 , Sinziana Stanescu  7 , Magdalena Ugarte  1 , Pedro Ruiz-Sala  1 , Belén Pérez  1
Affiliations

Lymphocyte Medium-Chain Acyl-CoA Dehydrogenase Activity and Its Potential as a Diagnostic Confirmation Tool in Newborn Screening Cases

Patricia Alcaide et al. J Clin Med. .

Abstract

The determination of acylcarnitines (AC) in dried blood spots (DBS) by tandem mass spectrometry in newborn screening (NBS) programs has enabled medium-chain acyl-coA dehydrogenase deficiency (MCADD) to be identified in presymptomatic newborns. Nevertheless, different confirmatory tests must be performed to confirm the diagnosis. In this work, we have collected and analyzed the NBS results and confirmatory test results (plasma AC, molecular findings, and lymphocyte MCAD activity) of forty individuals, correlating them with clinical outcomes and treatment, with the aim of obtaining useful diagnostic information that could be applied in the follow-up of the patients. Our results led us to classify patients into two groups. The first group (14 cases) had high increased octanoylcarnitine (C8) levels, biallelic pathogenic variants, and severe impaired enzyme activity (<10% of the intra-assay control (IAC)); all of these cases received nutritional therapy and required carnitine supplementation during follow-up, representing the most severe form of the disease. The second group (16 patients) was a heterogeneous group presenting moderate increases in C8, biallelic likely pathogenic/pathogenic variants, and intermediate activity (<41% IAC). All of them are currently asymptomatic and could be considered as having a milder form of the disease. Finally, eight cases presented a normal−mild increase in plasma C8, with only one pathogenic variant detected, and high−intermediate residual activity (15−100%). Based on our results, we confirm that combined evaluation of acylcarnitine profiles, genetic findings, and residual enzyme activities proves useful in predicting the risk of future metabolic decompensation, in making decisions regarding future treatment or follow-up, and also in confirming the clinical effects of unknown clinical variants.

Keywords: acylcarnitines; fatty acid oxidation; lymphocyte enzyme activity; medium-chain acyl-CoA dehydrogenase; newborn screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Enzymatic activity and correlation with genetic background of the patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rocha H., Castiñeiras D., Delgado C., Egea J., Yahyaoui R., González Y., Conde M., González I., Rueda I., Rello L., et al. JIMD Reports. Volume 16. Springer; Berlin/Heidelberg, Germany: 2014. Birth Prevalence of Fatty Acid β-Oxidation Disorders in Iberia; pp. 89–94. - DOI
    1. Hoflack M., Caruba C., Pitelet G., Haas H., Mas J.-C., Paquis V., Berard E. Coma du nourrisson aux urgences: 2 cas de déficit en MCAD. Arch. De Pédiatrie. 2010;17:1074–1077. doi: 10.1016/j.arcped.2010.03.011. - DOI - PubMed
    1. Feillet F., Ogier H., Cheillan D., Aquaviva C., Labarthe F., Baruteau J., Chabrol B., de Lonlay P., Valayanopoulos V., Garnotel R., et al. Déficit en acyl-CoA-déshydrogénase des acides gras à chaîne moyenne (MCAD): Consensus français pour le dépistage, le diagnostic, et la prise en charge. Arch. De Pédiatrie. 2012;19:184–193. doi: 10.1016/j.arcped.2011.10.025. - DOI - PubMed
    1. Jager E.A., Kuijpers M.M., Bosch A.M., Mulder M.F., Gozalbo E.R., Visser G., Vries M., Williams M., Waterham H.R., Spronsen F.J., et al. A Nationwide Retrospective Observational Study of Population Newborn Screening for Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency in the Netherlands. J. Inherit. Metab. Dis. 2019;42:890–897. doi: 10.1002/jimd.12102. - DOI - PubMed
    1. Wilcken B., Haas M., Joy P., Wiley V., Chaplin M., Black C., Fletcher J., McGill J., Boneh A. Outcome of Neonatal Screening for Medium-Chain Acyl-CoA Dehydrogenase Deficiency in Australia: A Cohort Study. Lancet. 2007;369:37–42. doi: 10.1016/S0140-6736(07)60029-4. - DOI - PubMed